Premier Asset Management LLC Intra Cellular Therapies, Inc. Transaction History

Premier Asset Management LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$35.2 - $53.42 $356,188 - $540,556	-10,119 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $933,170 - $1.38 Million	-32,492 Reduced 76.25%	10,119 $377,000
Q2 2021 Aug 16, 2021	BUY	$29.3 - $44.5 $883,453 - $1.34 Million	30,152 Added 242.01%	42,611 $1.74 Million
Q1 2021 May 12, 2021	SELL	$30.8 - $39.51 $435,727 - $558,947	-14,147 Reduced 53.17%	12,459 $423,000
Q4 2020 Feb 16, 2021	SELL	$23.34 - $32.22 $26,397 - $36,440	-1,131 Reduced 4.08%	26,606 $846,000
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $123,675 - $223,752	7,023 Added 33.9%	27,737 $712,000
Q2 2020 Jul 31, 2020	SELL	$14.35 - $26.64 $155,554 - $288,777	-10,840 Reduced 34.35%	20,714 $532,000
Q1 2020 May 07, 2020	BUY	$12.31 - $33.12 $388,429 - $1.05 Million	31,554 New	31,554 $485,000
Q3 2019 Nov 01, 2019	SELL	$7.47 - $14.03 $543,502 - $1.02 Million	-72,758 Closed	0 $0
Q2 2019 Aug 07, 2019	BUY	$10.65 - $14.29 $774,872 - $1.04 Million	72,758 New	72,758 $944,000
Q1 2019 May 15, 2019	SELL	$10.9 - $14.09 $690,013 - $891,953	-63,304 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$10.36 - $20.96 $655,829 - $1.33 Million	63,304 New	63,304 $721,000
Q2 2018 Aug 14, 2018	SELL	$17.33 - $23.4 $330,795 - $446,659	-19,088 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$15.16 - $25.49 $34,291 - $57,658	2,262 Added 13.44%	19,088 $402,000
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $22,874 - $26,914	-1,603 Reduced 8.7%	16,826 $244,000
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $198,480 - $407,280	18,429	18,429 $291,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.17B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Premier Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Premier Asset Management LLC with notifications on news.